<DOC>
	<DOCNO>NCT02171676</DOCNO>
	<brief_summary>Maximum tolerate dose ( MTD ) , safety , pharmacokinetic pharmacodynamic parameter , efficacy pulsatile administration BIBW 2992 combination docetaxel ( Taxotere® )</brief_summary>
	<brief_title>BIBW 2992 After Administration Docetaxel Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Male female patient confirm diagnosis advance , non resectable / metastatic solid tumor , type historically know express EGFR and/or HER2 , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment preferably patient breast , prostate , ovarian cancer . In addition , patient disease amenable standard treatment docetaxel Age 18 year old Life expectancy least three ( 3 ) month Written inform consent consistent International Conference Harmonization Good Clinical Practice guideline Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 Patients recover ( Common Terminology Criteria ( CTC ) Grade 0 1 ) therapyrelated toxicity previous chemo , hormone , immuno , radiotherapies Patients recover previous surgery The 12 additional patient recruit MTD must also meet follow criterion : Measurable tumor deposit ( Response Evaluation Criteria Solid Tumors ) one technique ( Xray , CT , MRI ) and/or recognize tumor marker prostate specific antigen ( prostate cancer ) cancer antigen 125 ( Ovarian cancer ) Active infectious disease Gastrointestinal disorder might interfere absorption study drug chronic diarrhea Serious illness concomitant nononcological disease consider investigator incompatible protocol Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least eight week , history cerebral edema bleed past eight week requirement steroid antiepileptic therapy Cardiac leave ventricular function rest ejection fraction CTC ≥ Grade 1 Absolute neutrophil count ( ANC ) less 1500 / mm3 Platelet count less 100 000 / mm3 Bilirubin &gt; upper limit normal ( ULN ) Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) &gt; 1.5 x ULN Alkaline Phosphatase &gt; 2.5 x ULN Serum creatinine &gt; 1.5 mg / dl ( &gt; 132 μmol / L , SI ( Système Internationale ) unit equivalent ) Women men sexually active unwilling use medically acceptable method contraception Pregnancy breastfeed Treatment investigational drug ; chemotherapy , immunotherapy , radiotherapy hormone therapy ( exclude luteinising hormonereleasing hormone agonist , hormone take breast cancer , bisphosphonates ) participation another clinical study within past four week start therapy concomitantly study Treatment EGFR HER2 inhibit drug within past four week start therapy concomitantly study ( 8 week trastuzumab ) Patients unable comply protocol Active alcohol drug abuse Hypersensitivity docetaxel component drug formulate polysorbate 80 The patient may eligible retreatment previous course finish . The patient eligible follow condition meet : If patient late Xray , CT MRI reveal progressive disease , clinical assessment reveals sign disease progression Cardiac leave ventricular function CTC Grade ≥ 2 time previous course Patients fulfil Exclusion Criteria list determine day 18 treatment course 1 ( visit 7 ) day 18 ( visit R5 ) previous course Patients recover doselimiting toxicity ( DLT ) 14 day onset . Recovery define return baseline level CTC Grade &lt; = 1 , whichever high</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>